International Journal for Parasitology: Drugs and Drug Resistance

Sponsored by the Australian Society for Parasitology

The International Journal for Parasitology – Drugs and Drug Resistance publishes the results of original research in the area of anti-parasite drug identification, development and evaluation, and parasite drug resistance. The journal also covers research into natural products as anti-parasitic agents, and bioactive parasite products. Studies can be aimed at unicellular or multicellular parasites of human or veterinary importance.

A list showing the types of articles that are considered is included below. Original research includes the development of novel and innovative concepts and ideas, as well as experimental and observational science that raises new hypotheses. Because of its breadth of organism coverage, all contributions should include relevant information about the parasite of interest in order to be comprehensible to non-experts in the particular subject of the articles. The principal form of publication is the full length article which contains substantial results from a major program of research. The journal also accepts brief reports that have similar subject scope as the full-length article, but do not merit a full-length publication.

In addition, the journal provides a medium for highlighting selected articles reporting highly significant original findings, as Editor's Choice Manuscripts. It also commissions articles with emphasis on shorter, focused Reviews of topical issues and strategically important subjects. The journal encourages critical comment and debate on matters of current controversy in the area of parasite drug resistance and anti-parasite drugs via "Current Opinions".

This title is fully open access and therefore funded not through library subscription payments but through author fees. If you would like your article to be published open access, but you genuinely cannot afford these fees, then individual waiver requests are considered on a case-by-case basis and may be granted in cases of genuine need. Priority for this waiver programme will be given to applications by authors from countries eligible for the Research4Life programme (see

Types of articles considered:

  • Compound library screening for inhibitors against enzymes or whole parasites
  • Drug target validation (chemical and/or genetic)
  • Drug target identification (must include some inhibitor studies rather than characterisation of an enzyme, for example)
  • Drug structure-activity relationship studies
  • Mechanisms of drug action and resistance
  • Reports of the development of drug resistance both in the field and laboratory
  • Studies on drug toxicity to the host (either on single host cells or whole organism)
  • Reports on toxicity in the field
  • Computational approaches to drug discovery or drug-target identification
  • Development of assays directed at screening for inhibitors
  • Drug combination studies
  • Natural products as anti-parasitic agents
  • Bioactive products produced by parasites
  • Use of live parasites as immunomodulatory agents
  • Epidemiological aspects of the emergence and spread of parasite drug resistance
  • Human clinical trials

Editors in Chief: Andrew Kotze , Kevin Saliba

Journal metrics

  • Imprint: ELSEVIER
  • ISSN: 2211-3207